Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells

British Journal of Haematology

Volumn 157, Issue 5, 2012, Pages 564-579

  Ramasamy, Karthik ^a,c   Khatun, Hazera ^a   MacPherson, Lee ^a   Caley, Mathew P ^b   Sturge, Justin ^b   Mufti, Ghulam J ^a,c   Schey, Stephen A ^a,c   Calle, Yolanda ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Co culture system; Dexamethasone; Drug resistance; Myeloma; Tumour microenvironment

Indexed keywords

ABELSON KINASE; BORTEZOMIB; DASATINIB; DEXAMETHASONE; DOXORUBICIN; ENHANCED GREEN FLUORESCENT PROTEIN; IMATINIB; MELPHALAN;

ACTIN FILAMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL LABELING; CELL NUCLEUS; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; FIBROBLAST CULTURE; FLUORESCENCE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MYELOMA CELL; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STROMA CELL; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ACTINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; BONE RESORPTION; CELL LINE; CELL PROLIFERATION; COCULTURE TECHNIQUES; DEXAMETHASONE; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MULTIPLE MYELOMA; ONCOGENE PROTEINS V-ABL; OSTEOCLASTS; PYRIMIDINES; SRC-FAMILY KINASES; STROMAL CELLS; THIAZOLES; TUMOR MICROENVIRONMENT;

EID: 84860839794     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09103.x     Document Type: Article

References (44)

1. Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., Inoue, D. & Matsumoto, T. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood, 104, 2484-2491.
2. Albrecht, M., Janssen, M., Konrad, L., Renneberg, H. & Aumuller, G. (2002) Effects of dexamethasone on proliferation of and fibronectin synthesis by human primary prostatic stromal cells in vitro. Andrologia, 34, 11-21.
3. Anderson, K.C., Shaughnessy, Jr, J.D., Barlogie, B., Harousseau, J.L. & Roodman, G.D. (2002) Multiple myeloma. American Society of Hematology Education Program, 21, 4-240.
4. Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V., Donnenberg, A., Ghobrial, I., Mapara, M.Y., Stirling, D., Roodman, D. & Lentzsch, S. (2006) Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 107, 3098-3105.
5. Azab, A.K., Runnels, J.M., Pitsillides, C., Moreau, A.S., Azab, F., Leleu, X., Jia, X., Wright, R., Ospina, B., Carlson, A.L., Alt, C., Burwick, N., Roccaro, A.M., Ngo, H.T., Farag, M., Melhem, M.R., Sacco, A., Munshi, N.C., Hideshima, T., Rollins, B.J., Anderson, K.C., Kung, A.L., Lin, C.P. & Ghobrial, I.M. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood, 113, 4341-4351.
6. Boyce, B.F., Yoneda, T., Lowe, C., Soriano, P. & Mundy, G.R. (1992) Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. Journal of Clinical Investigation, 90, 1622-1627.
7. Calle, Y., Jones, G.E., Jagger, C., Fuller, K., Blundell, M.P., Chow, J., Chambers, T. & Thrasher, A.J. (2004) WASp deficiency in mice results in failure to form osteoclast sealing zones and defects in bone resorption. Blood, 103, 3552-3561.
8. Calle, Y., Burns, S., Thrasher, A.J. & Jones, G.E. (2006) The leukocyte podosome. European Journal of Cell Biology, 85, 151-157.
9. Chou, T.C. & Talalay, P. (1984) Quantitative analysis of dose-effect relashionships:the combined effects of multiple drugs or enzume inhibitors. Advances in Enzyme Regulation, 22, 27-55.
10. Coluccia, A.M., Cirulli, T., Neri, P., Mangieri, D., Colanardi, M.C., Gnoni, A., Di, R.N., Dammacco, F., Tassone, P., Ribatti, D., Gambacorti-Passerini, C. & Vacca, A. (2008) Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood, 112, 1346-1356.
11. Copland, M., Hamilton, A., Elrick, L.J., Baird, J.W., Allan, E.K., Jordanides, N., Barow, M., Mountford, J.C. & Holyoake, T.L. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107, 4532-4539.
12. Du, W., Hattori, Y., Hashiguchi, A., Kondoh, K., Hozumi, N., Ikeda, Y., Sakamoto, M., Hata, J. & Yamada, T. (2004) Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathology International, 54, 285-294.
13. Flaberg, E., Markasz, L., Petranyi, G., Stuber, G., Dicso, F., Alchihabi, N., Olah, E., Csizy, I., Jozsa, T., Andren, O., Johansson, J.E., Andersson, S.O., Klein, G. & Szekely, L. (2010) High-throughput live-cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts. International Journal of Cancer, 128, 2793-2802.
14. Gilbert, L.A. & Hemann, M.T. (2010) DNA damage-mediated induction of a chemoresistant niche. Cell, 143, 355-366.
15. Gregoretti, M.G., Gottardi, D., Ghia, P., Bergui, L., Merico, F., Marchisio, P.C. & Caligaris-Cappio, F. (1994) Characterization of bone marrow stromal cells from multiple myeloma. Leukemia Research, 18, 675-682.
16. Horne, W.C., Sanjay, A., Bruzzaniti, A. & Baron, R. (2005) The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunological Reviews, 208, 106-125.
17. Id, B.H., Lagneaux, L., Najar, M., Piccart, M., Ghanem, G., Body, J.J. & Journe, F. (2010) The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer, 10, 298.
18. Lakkakorpi, P.T. & Vaananen, H.K. (1996) Cytoskeletal changes in osteoclasts during the resorption cycle. Microscopy Research and Technique, 33, 171-181.
19. Lee, S.Y., Lim, J., Khang, G., Son, Y., Choung, P.H., Kang, S.S., Chun, S.Y., Shin, H.I., Kim, S.Y. & Park, E.K. (2009) Enhanced ex vivo expansion of human adipose tissue-derived mesenchymal stromal cells by fibroblast growth factor-2 and dexamethasone. Tissue Engineering Part A, 15, 2491-2499.
20. Li, X., Ling, W., Pennisi, A., Khan, S. & Yaccoby, S. (2009) Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Letters, 284, 175-181.
21. Luo, F.R., Camuso, A., McGlinchey, K., Fager, K., Flefleh, C., Wen, M.-L., Smykla, R., Wescott, D., Tamasi, J., Feyen, J., Hunt, J., Kramer, R. & Lee, F. (2005) Evaluation of anti-osteoclastic activity of the novel, oral multi-targeted kinase inhibitor dasatinib (BMS- 354825). Proceedings of the Molecular Targets and Cancer Therapeutics Meeting, page 173, Abstract B178. ©2001-2012 American Association for Cancer Research, Philadelphia, PA.
22. Marzia, M., Sims, N.A., Voit, S., Migliaccio, S., Taranta, A., Bernardini, S., Faraggiana, T., Yoneda, T., Mundy, G.R., Boyce, B.F., Baron, R. & Teti, A. (2000) Decreased c-Src expression enhances osteoblast differentiation and bone formation. The Journal of Cell Biology, 151, 311-320.
23. McMillin, D.W., Delmore, J., Weisberg, E., Negri, J.M., Geer, D.C., Klippel, S., Mitsiades, N., Schlossman, R.L., Munshi, N.C., Kung, A.L., Griffin, J.D., Richardson, P.G., Anderson, K.C. & Mitsiades, C.S. (2010) Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nature Medicine, 16, 483-489.
24. Moreau, P., Coiteux, V., Hulin, C., Leleu, X., van de Velde, H., Acharya, M. & Harousseau, J.L. (2008) Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica, 93, 1908-1911.
25. Noborio-Hatano, K., Kikuchi, J., Takatoku, M., Shimizu, R., Wada, T., Ueda, M., Nobuyoshi, M., Oh, I., Sato, K., Suzuki, T., Ozaki, K., Mori, M., Nagai, T., Muroi, K., Kano, Y., Furukawa, Y. & Ozawa, K. (2009) Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene, 28, 231-242.
26. O'Brien, C.A., Jia, D., Plotkin, L.I., Bellido, T., Powers, C.C., Stewart, S.A., Manolagas, S.C. & Weinstein, R.S. (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology, 145, 1835-1841.
27. O'Sullivan, B.T., Cutler, D.J., Hunt, G.E., Walters, C., Johnson, G.F. & Caterson, I.D. (1997) Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biological Psychiatry, 41, 574-584.
28. Pearse, R.N., Sordillo, E.M., Yaccoby, S., Wong, B.R., Liau, D.F., Colman, N., Michaeli, J., Epstein, J. & Choi, Y. (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 98, 11581-11586.
29. Peng, B., Hayes, M., Resta, D., Racine-Poon, A., Druker, B.J., Talpaz, M., Sawyers, C.L., Rosamilia, M., Ford, J., Lloyd, P. & Capdeville, R. (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology, 22, 935-942.
30. Phekoo, K.J., Schey, S.A., Richards, M.A., Bevan, D.H., Bell, S., Gillett, D. & Moller, H. (2004) A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. British Journal of Haematology, 127, 299-304.
31. Podar, K., Chauhan, D. & Anderson, K.C. (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 23, 10-24.
32. Raaijmakers, M.H., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J.A., Ebert, B.L., Al-Shahrour, F., Hasserjian, R.P., Scadden, E.O., Aung, Z., Matza, M., Merkenschlager, M., Lin, C., Rommens, J.M. & Scadden, D.T. (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature, 464, 852-857.
33. Ribeiro, D.L., Rafacho, A., Bosqueiro, J.R., Taboga, S.R. & Goes, R.M. (2008) Cellular changes in the prostatic stroma of glucocorticoid-treated rats. Cell and Tissue Research, 332, 499-508.
34. Saad, F. (2009) Src as a therapeutic target in men with prostate cancer and bone metastases. BJU International, 103, 434-440.
35. van Steensel, L., Paridaens, D., Schrijver, B., Dingjan, G.M., van Daele, P.L., van Hagen, P.M., van den Bosch, W.A., Drexhage, H.A., Hooijkaas, H. & Dik, W.A. (2009) Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy. Investigative Ophthalmology & Visual Science, 50, 3091-3098.
36. Sturge, J., Caley, M.P. & Waxman, J. (2011) Bone metastasis in prostate cancer: emerging therapeutic strategies. Nature Reviews. Clinical Oncology, 8, 357-368.
37. Terpos, E., Sezer, O., Croucher, P. & Dimopoulos, M.A. (2007) Myeloma bone disease and proteasome inhibition therapies. Blood, 110, 1098-1104.
38. Vanderkerken, K., De Leenheer, E., Shipman, C., Asosingh, K., Willems, A., Van Camp, B. & Croucher, P. (2003) Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Research, 63, 287-289.
39. Vandyke, K., Dewar, A.L., Farrugia, A.N., Fitter, S., Bik, T.L., Hughes, T.P. & Zannettino, A.C. (2009) Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 23, 994-997.
40. Vandyke, K., Dewar, A.L., Diamond, P., Fitter, S., Schultz, C.G., Sims, N.A. & Zannettino, A.C. (2010) The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 25, 1759-1770.
41. Wildes, T.M., Procknow, E., Gao, F., Dipersio, J.F. & Vij, R. (2009) Dasatinib in relapsed or plateau-phase multiple myeloma. Leukemia & Lymphoma, 50, 137-140.
42. Yaccoby, S., Pearse, R.N., Johnson, C.L., Barlogie, B., Choi, Y. & Epstein, J. (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British Journal of Haematology, 116, 278-290.
43. Yaccoby, S., Wezeman, M.J., Henderson, A., Cottler-Fox, M., Yi, Q., Barlogie, B. & Epstein, J. (2004) Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Research, 64, 2016-2023.
44. Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L. & Trono, D. (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnology, 15, 871-875.